MSF's Suerie Moon spoke in front of a US Senate Committee on promoting new treatments & cures for neglected diseases read more
NEW: The 13th Edition of Untangling the Web of Antiretroviral Price Reductions is now available download it here
VIDEO: MSF's community approach to treating malnutrition in Niger watch it here
WHO's work on the financing of medical research and development is given a fresh start read more
MSF Letter to GFATM on concerns over scale-up of AIDS treatment in light of Board of Directors Meeting read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
|
 |
|
 |
Calling all governments: Put patients’ needs first.
MSF Medical Coordinator, Liesbet Ohler talks of Charles, a two year-old child whose death she couldn’t prevent because of ineffective or unadapted tools for TB, for HIV and particularly for children. Click here
Dying for a test: breaking the cycle of neglect
Access Campaign biologist Martine Usdin answers questions on TB diagnostics: what are the problems with the tests today? Are they suited to HIV/TB or drug-resistance? What do the tests of the future need to look like? What needs to happen so that those tests can be developed? Click here
Is Aids a neglected disease?
MSF HIV doctor Alexandra Calmy explains why despite all the research that goes on in the West, the needs of HIV patients in developing countries, in particular women and children, go largely unanswered. She tells what the IGWG about R&D and access to antiretrovirals. Click here
Falling through the cracks: working to fight Chagas disease with limited tools
MSF doctors in Bolivia answer our questions: why is detecting and treating Chagas so difficult? How do you make do with tests and drugs that are worth using, but not nearly safe or effective enough to accept as the only option? What needs to change? Click here
'Outrageous' cost of medicine condemns patients to blindness
MSF's Dr.Peter Saranchuk talks about MSF’s attempts to save patients’ sight or life by treating CMV in China. Affordable treatment for CMV retinitis exists, but involves injecting patients directly into the eyes. Better treatments are too expensive – US$10,000 per patient course – and Roche’s offer for lower prices come with too many strings attached. Click here
Click here 
to read the full document including essays on alternative methods of stimulating R&D for diseases that mainly affect people in developing countries
Cough Up for TB! The Underfunding of TB Research Across Europe (October 2009) 
Presenation: Missing ARVs for HIV/AIDS treatment in 2009 - Unitaid Patent Pool Briefing
HIV/AIDS treatment in developing countries: the battle for long-term survival has just begun
